Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exjade in MDS, Thalassemia, and Rare Anemias with Iron Overload
NCT01250951Phase 4Completed
- Sponsor
- Novartis
- Start
- Dec 2009
- Primary completion
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of deferasirox in iron overload, sponsored by Novartis. Primary endpoint: Serum Ferritin at 12 months. Started Dec 2009; status: completed.
02
Drugs
deferasirox
03
Conditions
iron overload
Beyond the preview
Go deeper on NCT01250951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01250951.